N-formyl peptide receptors (FPR1, FPR2, and FPR3) play key roles in the regulation of inflammatory processes, and recently, it was demonstrated that FPR1 and FPR2 have a dual role in the progression/suppression of some cancers. Therefore, FPRs represent an important therapeutic target for the treatment of both cancer and inflammatory diseases. Previously, we identified selective or mixed FPR agonists with pyridazinone or pyridinone scaffolds showing a common 4-(bromophenyl)acetamide fragment, which was essential for activity. We report here new pyrazole and pyrazolone derivatives as restricted analogues of the above 6-membered compounds, all exhibiting the same 4-bromophenylacetamide side chain. Most new products had low or absent FPR agonist activity, suggesting that the pyrazole nucleus was not appropriate for FPR agonists. This hypothesis was confirmed by molecular modeling studies, which highlighted that the five-membered scaffold was responsible for a worse arrangement of the molecules in the receptor binding site.

Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists / Vergelli C.; Khlebnikov A.I.; Crocetti L.; Guerrini G.; Cantini N.; Kirpotina L.N.; Schepetkin I.A.; Cilibrizzi A.; Quinn M.T.; Rossi P.; Paoli P.; Giovannoni M.P.. - In: CHEMICAL BIOLOGY & DRUG DESIGN. - ISSN 1747-0277. - ELETTRONICO. - 98:(2021), pp. 582-603. [10.1111/cbdd.13913]

Synthesis, biological evaluation, molecular modeling, and structural analysis of new pyrazole and pyrazolone derivatives as N-formyl peptide receptors agonists

Vergelli C.;Crocetti L.
;
Guerrini G.;Cantini N.;Cilibrizzi A.;Rossi P.;Paoli P.;Giovannoni M. P.
2021

Abstract

N-formyl peptide receptors (FPR1, FPR2, and FPR3) play key roles in the regulation of inflammatory processes, and recently, it was demonstrated that FPR1 and FPR2 have a dual role in the progression/suppression of some cancers. Therefore, FPRs represent an important therapeutic target for the treatment of both cancer and inflammatory diseases. Previously, we identified selective or mixed FPR agonists with pyridazinone or pyridinone scaffolds showing a common 4-(bromophenyl)acetamide fragment, which was essential for activity. We report here new pyrazole and pyrazolone derivatives as restricted analogues of the above 6-membered compounds, all exhibiting the same 4-bromophenylacetamide side chain. Most new products had low or absent FPR agonist activity, suggesting that the pyrazole nucleus was not appropriate for FPR agonists. This hypothesis was confirmed by molecular modeling studies, which highlighted that the five-membered scaffold was responsible for a worse arrangement of the molecules in the receptor binding site.
2021
98
582
603
Goal 3: Good health and well-being for people
Vergelli C.; Khlebnikov A.I.; Crocetti L.; Guerrini G.; Cantini N.; Kirpotina L.N.; Schepetkin I.A.; Cilibrizzi A.; Quinn M.T.; Rossi P.; Paoli P.; Gi...espandi
File in questo prodotto:
File Dimensione Formato  
2021 Chem Biol Drug Des .pdf

accesso aperto

Tipologia: Pdf editoriale (Version of record)
Licenza: Open Access
Dimensione 3.35 MB
Formato Adobe PDF
3.35 MB Adobe PDF

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1244537
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact